SEOUL – 3billion, a South Korean genetic analysis company, has announced a partnership with AstraZeneca Korea to accelerate the diagnosis of atypical Hemolytic Uremic Syndrome (aHUS), a rare and life-threatening disease.   

The two companies signed a Memorandum of Understanding (MOU) on May 17th to develop a genetic testing system that can deliver results within two weeks. This is a significant improvement over current methods, which can take up to six weeks.

aHUS is a rare disease that causes abnormal blood clots to form in small blood vessels. This can lead to serious complications, such as kidney failure, stroke, and heart attack. Early diagnosis and treatment are critical to improving outcomes for patients with aHUS.   

However, diagnosing aHUS can be challenging. There is no single definitive test for the disease, and it can be difficult to distinguish from other conditions. Genetic testing is the most accurate way to confirm a diagnosis of aHUS, but current methods are too slow to be useful in many cases.   

3billion's AI-powered genetic diagnosis system is designed to address this challenge. The system can analyze up to 5 million genetic variations per patient with 99.4% accuracy. This allows for rapid identification of the genetic mutations that cause aHUS.   

"We are committed to providing patients with aHUS with the most rapid and accurate genetic testing possible," said Dr. Changwon Keum, CEO of 3billion. "Our AI-powered system will enable us to identify the genetic causes of aHUS in a matter of days, rather than weeks."

AstraZeneca Korea is providing its C5 inhibitor therapies, Soliris® and Ultomiris®, for the treatment of aHUS patients in South Korea. Both drugs are approved for use in aHUS and are covered by national health insurance.

"We are excited to partner with 3billion to improve the diagnosis and treatment of aHUS in South Korea," said Hoseon Jeon, CEO of AstraZeneca Korea. "By working together, we can ensure that patients with aHUS receive the timely care they need."

The partnership between 3billion and AstraZeneca Korea is a major step forward in the fight against aHUS. By reducing the time to diagnosis, the two companies are giving patients a better chance of survival and a higher quality of life.

About 3billion

3billion is a genetic analysis company that uses AI to accelerate the diagnosis of rare diseases. The company's mission is to make genetic testing more accessible and affordable for patients around the world.   

About AstraZeneca Korea

AstraZeneca Korea is a subsidiary of AstraZeneca, a global biopharmaceutical company. AstraZeneca is focused on the discovery, development, and commercialization of prescription medicines primarily for the treatment of diseases in three main therapy areas - Oncology; Cardiovascular, Renal & Metabolism; and Respiratory.   

소스 및 관련 콘텐츠

[Copyright (c) Global Economic Times. All Rights Reserved.]